Blood Screening Market Research Report - Forecast till 2030

Blood Screening Market: By Technology (Nucleic Acid Amplification Test, Enzyme-Linked Immunosorbent Assay, Next-Generation Sequencing), Product and Services (Reagents, Instruments) and End User (Hospitals and Clinics) - Forecast till 2030

ID: MRFR/MED/5434-HCR | August 2022 | Region: Global | 85 Pages         

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Blood Screening Market, by Technology

6.1 Introduction

6.2 Nucleic Acid Amplification Test (NAT)

6.2.1 Transcription-Mediated Amplification (TMA)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.2.2 Real-Time Polymerase Chain Reaction (PCR)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3 Enzyme-Linked Immunosorbent Assay (ELISA)

6.3.1 ELISA Market, By Platform

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3.2 ELISA Market, By Generation

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4 Rapid Tests

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.5 Next-Generation Sequencing (NGS)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.6 Western Blotting

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 7. Global Blood Screening Market, by Product and Services

7.1 Introduction

7.2 Reagent and kits

7.2.1 NAT Reagents & Kits

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.2.2 ELISA Reagents & Kits

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3 Enzymes and Polymerases

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.4 Standards and Controls

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.5 Probes and Primers

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.6 Buffers, Nucleotides, and Solutions

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.7 Immunosorbents

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.8 Controls

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.9 Instruments

7.3.1 Rental Purchase

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3.2 Outright Purchase

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.4 Software and services

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 8. Global Blood Screening Market, By End User

8.1 Hospitals

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.2 Clinics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.3 Research Institutes and Academic Center

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.4 Blood Banks

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.5 Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 9. Global Blood Screening Market, by Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia-Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 South Korea

9.4.6 Rest of Asia-Pacific

9.5 Middle East & Africa

9.5.1 Middle East

9.5.2 Africa

Chapter 10. Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

Chapter 11. Company Profiles

11.1 Grifols

11.1.1 Company Overview

11.1.2 Product and Services Overview

11.1.3 Financials Overview

11.1.4 Key Developments

11.1.5 SWOT Analysis

11.2 F. Hoffmann-La Roche

11.2.1 Company Overview

11.2.2 Product and Services Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Abbott Laboratories

11.3.1 Company Overview

11.3.2 Product and Services Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Biomérieux

11.4.1 Company Overview

11.4.2 Product and Services Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Bio-Rad Laboratories, Inc.

11.5.1 Company Overview

11.5.2 Product and Services Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.6 Siemens Healthineers (A Subsidiary of Siemens AG)

11.6.1 Company Overview

11.6.2 Product and Services Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.7 Ortho Clinical Diagnostics, Inc.

11.7.1 Overview

11.7.2 Product and Services Overview

11.7.3 Financial Overview

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Thermo Fisher Scientific, Inc.

11.8.1 Overview

11.8.2 Product and Services Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.9 Beckman Coulter (A Subsidiary of Danaher Corporation)

11.9.1 Overview

11.9.2 Product and Services Overview

11.9.3 Financials

11.9.4 Key Developments

11.9.5 SWOT Analysis

11.10 Becton, Dickinson and Company

11.10.1 Overview

11.10.2 Product and Services Overview

11.10.3 Financials

11.10.4 Key Developments

11.10.5 SWOT Analysis

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s Viewpoint

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Predictions for the Blood Screening Market Industry

Chapter 13. Appendix

LIST OF TABLES:

Table 1 Global Blood Screening Market Synopsis, 2020-2027

Table 2 Global Blood Screening Market Estimates and Forecast, 2020-2027 (USD Million)

Table 3 Global Blood Screening Market, by Region, 2020-2027 (USD Million)

Table 4 Global Blood Screening Market, by Technology, 2020-2027 (USD Million)

Table 5 Global Blood Screening, by Product and Services, 2020-2027 (USD Million)

Table 6 Global Blood Screening Market, by End User, 2020-2027 (USD Million)

Table 7 North America: Blood Screening Market, by Technology, 2020-2027 (USD Million)

Table 8 North America: Blood Screening, by Product and Services, 2020-2027 (USD Million)

Table 9 North America: Blood Screening Market, by End User, 2020-2027 (USD Million)

Table 10 US: Blood Screening Market, by Technology, 2020-2027 (USD Million)

Table 11 US: Blood Screening Market, by Product and Services, 2020-2027 (USD Million)

Table 12 US: Blood Screening Market, by End User, 2020-2027 (USD Million)

Table 13 Canada: Blood Screening Market, by Technology, 2020-2027 (USD Million)

Table 14 Canada: Blood Screening Market, by Product and Services, 2020-2027 (USD Million)

Table 15 Canada: Blood Screening Market, by End User, 2020-2027 (USD Million)

Table 16 South America: Blood Screening Market, by Technology, 2020-2027 (USD Million)

Table 17 South America: Blood Screening Market, by Product and Services, 2020-2027 (USD Million)

Table 18 South America: Blood Screening Market, by End User, 2020-2027 (USD Million)

Table 19 Europe: Blood Screening Market, by Technology, 2020-2027 (USD Million)

Table 20 Europe: Blood Screening Market, by Product and Services, 2020-2027 (USD Million)

Table 21 Europe: Blood Screening Market, by End User, 2020-2027 (USD Million)

Table 22 Western Europe: Blood Screening Market, by Technology, 2020-2027 (USD Million)

Table 23 Western Europe: Blood Screening Market, by Product and Services, 2020-2027 (USD Million)

Table 24 Western Europe: Blood Screening Market, by End User, 2020-2027(USD Million)

Table 25 Eastern Europe: Blood Screening Market, by Technology, 2020-2027 (USD Million)

Table 26 Eastern Europe: Blood Screening Market, by Product and Services, 2020-2027 (USD Million)

Table 27 Eastern Europe: Blood Screening Market, by End User, 2020-2027 (USD Million)

Table 28 Asia-Pacific: Blood Screening Market, by Technology, 2020-2027 (USD Million)

Table 29 Asia-Pacific: Blood Screening Market, by Product and Services, 2020-2027 (USD Million)

Table 30 Asia-Pacific: Blood Screening Market, by End User, 2020-2027 (USD Million)

Table 31 Middle East & Africa: Blood Screening by Market, by Technology, 2020-2027 (USD Million)

Table 32 Middle East & Africa: Blood Screening Market, by Product and Services, 2020-2027 (USD Million)

Table 33 Middle East & Africa Blood Screening Market, by End User, 2020-2027 (USD Million)

LIST OF FIGURES:

Figure 1 Research Process

Figure 2 Market Structure for Global Blood Screening Market

Figure 3 Market Dynamics for Global Blood Screening Market

Figure 4 Global Blood Screening Market Share, by Technology, 2020

Figure 5 Global Blood Screening Market Share, by Product and Services, 2020

Figure 6 Global Blood Screening Market Share, by End User, 2020

Figure 7 Global Blood Screening Market Share, by Region, 2020

Figure 8 North America: Blood Screening Market Share, by Country, 2020

Figure 9 Europe: Blood Screening Market Share, by Country, 2020

Figure 10 Asia-Pacific: Blood Screening Market Share, by Country, 2020

Figure 11 Middle East & Africa: Blood Screening Market Share, by Country, 2020

Figure 12 Global Blood Screening Market: Company Share Analysis, 2020 (%)

Figure 13 Grifols: Key Financials

Figure 14 Grifols: Segmental Revenue

Figure 15 Grifols: Geographical Revenue

Figure 16F. Hoffmann-La Roche: Key Financials

Figure 17F. Hoffmann-La Roche: Segmental Revenue

Figure 18F. Hoffmann-La Roche: Geographical Revenue

Figure 19Abbott Laboratories: Key Financials

Figure 20Abbott Laboratories: Segmental Revenue

Figure 21Abbott Laboratories: Geographical Revenue

Figure 22Biomérieux: Key Financials

Figure 23Biomérieux: Segmental Revenue

Figure 24Biomérieux: Geographical Revenue

Figure 25Bio-Rad Laboratories, Inc.: Key Financials

Figure 26Bio-Rad Laboratories, Inc.: Segmental Revenue

Figure 27Bio-Rad Laboratories, Inc.: Geographical Revenue

Figure 28Siemens Healthineers (A Subsidiary of Siemens AG): Key Financials

Figure 29Siemens Healthineers (A Subsidiary of Siemens AG): Segmental Revenue

Figure 30 Siemens Healthineers (A Subsidiary of Siemens AG): Geographical Revenue

Figure 31Ortho Clinical Diagnostics, Inc.: Key Financials

Figure 32Ortho Clinical Diagnostics, Inc.: Segmental Revenue

Figure 33Ortho Clinical Diagnostics, Inc.: Geographical Revenue

Figure 34Thermo Fisher Scientific, Inc.: Key Financials

Figure 35Thermo Fisher Scientific, Inc.: Segmental Revenue

Figure 36Thermo Fisher Scientific, Inc.: Geographical Revenue

Figure 37Beckman Coulter (A Subsidiary of Danaher Corporation): Key Financials

Figure 38 Beckman Coulter (A Subsidiary of Danaher Corporation): Segmental Revenue

Figure 39 Beckman Coulter (A Subsidiary of Danaher Corporation): Geographical Revenue

Figure 40Becton, Dickinson and Company: Key Financials

Figure 41Becton, Dickinson and Company: Segmental Revenue

Figure 42Becton, Dickinson and Company: Geographical Revenue

Blood Screening Market

The global blood screening market is projected to reach USD 3.9 billion by 2026 at a CAGR of 8.8% during the ongoing forecast period 2022-2030.

Segmentation

By Technology Nucleic Acid Amplification Test Enzyme Linked Immunosorbent Assay Next Generation Sequencing
By Product and Services Reagents Instrument
By End User Hospitals Clinics

Key Players

  • Biomérieux
  • Bio-Rad LaboratoriesInc.
  • Siemens Healthineers (A Subsidiary of Siemens AG)
  • Ortho Clinical DiagnosticsInc.
  • Thermo Fisher ScientificInc

Drivers

  • Increasing number of blood donations and blood donors
  • Increasing awareness about the safety of donated blood
Speak to Analyst Request a Free Sample

Blood Screening Market Overview
 
The Blood Screening Market is expected to register a growth of significant CAGR 8.10% during the forecast period (2022–2030). One of the most recommended and preferred tests for diagnosing several infectious diseases is blood screening. Blood screening allows physicians to diagnose diseases actively, which aids in managing suitable treatments and monitoring the patients to avoid the spread of the disease. Elements such as the increase in blood donations and blood transfusion-related screenings, rising generality of infectious diseases, increasing geriatric population, and rising awareness about transfusion-transmitted diseases are boosting the growth of this market. Unexploited coming out markets such as India and China, and improvements in technologies carry great opportunities for the market to grow during the anticipated period. However, the absence of legislation, rules, regulations, and policies concerning blood transfusion-related activities in some nations and the improvement of alternative technologies restoring blood screening are projected to hamper the growth of this market to a certain level.

Segmentation:


The Blood Screening Market has been segmented on the devices, service providers, application, end users.


On the basis of technology, the market has been classified as nucleic acid amplification test (NAT), enzyme-linked immunosorbent assay (ELISA), rapid tests, next-generation sequencing (NGS), western blotting. The nucleic acid amplification test is segmented in to transcription-mediated amplification (TMA) and real-time polymerase chain reaction (PCR). The enzyme-linked immunosorbent assay is segmented in to ELISA market, by platform and ELISA market, by generationOn the basis of products and services, the market has been classified as reagent and kits, enzymes and polymerases, standards and controls, probes and primers, buffers, nucleotides, and solutions, immunosorbents, instruments and software and services. The reagent and kits have been segmented in to NAT reagents & kits, ELISA reagents & kits. The instruments have been segmented in to rental purchase and outright purchase.


On the basis of end users, the market has been classified as hospitals, clinics, research institutes and academic centers, blood banks and others.On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.


The European arrhythmia monitoring devices market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The Blood Screening Market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. TheBlood Screening Marketin the Middle East and Africa has been segmented into the Middle East and Africa.


Regional Market Summary:


Global Blood Screening Market Share, by Region, 2017 (%)


Source: MRFR Analysis


In the Blood Screening Market, North America is anticipated to account for largest market share due to the early adoption of advanced medical technologies, continuous development by companies operating into drugs. According to America’s Blood organization 1 in 7 people entering the hospitals needs blood. According to American Red Cross, less than 38 percent of the population is eligible to give blood or platelets. According to Centers for Disease Control and Prevention (CDC), there are more than 9.5 Million blood donors in the United States and an estimated 5 million patients who receive blood annually, resulting in a total of 14.6 Million transfusions per year.


The European market is expected to hold the second largest market share. Factors such as a rise in research expenses, advancement of technology, the decline in human health, and the necessity for innovative and effective therapies boost the growth of the market in this region. According to World Health Organization (WHO) the average number of donations across the European Region ranges from 6 to 67.6 per 1000 inhabitants, with Demark reporting the highest blood donation rate.


Whereas the market share in Asia-Pacific region is also anticipated to experience growth in the near future due to access to optimal treatment facilities and growing demand for increasing government initiatives, advanced technology, better adoption rate, and rising healthcare expenditure. Countries in the Asia pacific region, such as China and India, are the hotspots for investment opportunities due to treatment and research activities, growing number of partnerships and healthcare modernization, growing rate of diagnosis, quality improvisations.


The market in the Middle East & Africa is expected to account for the smallest share of the blood screening market due to an underdeveloped healthcare sector, the dearth of technical knowledge, and poor medical facilities.


Key Players:


Some of the key players in the Blood Screening Market Grifols, F. Hoffmann-La Roche, Abbott Laboratories, Biomérieux, Bio-Rad Laboratories, Inc., Siemens Healthineers (A Subsidiary of Siemens AG), Ortho Clinical Diagnostics, Inc., Thermo Fisher Scientific, Inc., Beckman Coulter (A Subsidiary of Danaher Corporation) and Becton, Dickinson and Company.


Blood Screening Market, by Technology:



  •      Nucleic Acid Amplification Test (NAT)

    •     Transcription-Mediated Amplification (TMA)

    •     Real-Time Polymerase Chain Reaction (PCR)



  •       Enzyme-Linked Immunosorbent Assay (ELISA)

    •     ELISA Market, By Platform

    •     ELISA Market, By Generation



  •       Rapid Tests

  •       Next-Generation Sequencing (NGS)

  •       Western Blotting


Blood Screening Market, by Product and Services:



  •      Reagent and kits

    •     NAT Reagents & Kits

    •     ELISA Reagents & Kits



  •       Enzymes and Polymerases

  •       Standards and Controls

  •       Probes and Primers

  •       Buffers, Nucleotides, and Solutions

  •       Immunosorbents

  •       Instruments

    •      Rental Purchase

    •      Outright Purchase



  •       Software and services


Blood Screening Market, by End-Users:



  •      Hospitals

  •      Clinics

  •      Research Institutes and Academic Centers

  •      Blood Banks

  •      Others


Blood Screening Market, by Region:



  •      Americas   

    •  North America   

      •  US

      •     Canada



    •  South America



  •      Europe   

    • Western Europe     

      •      Germany

      •      France

      •      Italy

      •      Spain

      •      UK

      •      Rest of Western Europe



    •     Eastern Europe



  •       Asia-Pacific   

    •     Japan

    •     China

    •     India

    •     Australia

    •     South Korea

    •     Rest of Asia-Pacific



  •       Middle East & Africa   

    •  Middle East

    •     Africa




Recent Development


The covid-19 pandemic has severely affected the global blood screening market both negatively and positively. The outburst of the covid-19 pandemic led to the sudden development or improvement in various serological tests to identify covid-19 antibodies by many healthcare industries. However, the USA-FDA accepted the emergency use authorization (EUA) for about fifty serological tests to identify covid-19 antibodies. These tests are considered to observe the seroprevalence of the virus in a certain population. However, there has been a drastic rise in the number of hospitalizations, which is projected to increase the ultimatum for donated blood or its elements and positively affect the blood screening market, whereas, in August 2020, the USA-FDA accommodate an emergency use authorization for the plasma treatment covid-19 in hospitalized patients.

Intended Audience:



  • Blood Screening Instruments and Reagents Manufacturers

  • Blood Screening Software and Services Providers

  • Blood Banks

  • Hospitals

  • Red Cross Societies

  • Regulatory Bodies

  • Research and Consulting Firms

  • Government Bodies



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   8.10% (2020-2030)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Devices, Service Providers, Application, End users
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Grifols, F. Hoffmann-La Roche, Abbott Laboratories, Biomérieux, Bio-Rad Laboratories, Inc., Siemens Healthineers (A Subsidiary of Siemens AG), Ortho Clinical Diagnostics, Inc., Thermo Fisher Scientific, Inc., Beckman Coulter (A Subsidiary of Danaher Corporation) and Becton, Dickinson and Company
  Key Market Opportunities

  • Increasing affordability and adoption of nucleic acid test (NAT) for blood screening
  • Growing prevalence of infectious diseases
  •   Key Market Drivers

  • Increasing number of blood donations and blood donors
  • Increasing awareness about the safety of donated blood


  • Speak to Analyst Ask for Customization